title: Concurrent application of tretinoin (retinoic acid) partially protects against corticosteroid-induced epidermal atrophy.
abstract: Cutaneous atrophy arising from prolonged use of potent topical corticosteroids has long been a concern. Thus, it would be advantageous to find an agent which protects against atrophy produced by corticosteroids but at the same time does not impair their anti-inflammatory effects. Recent work shows that topical all-trans retinoic acid (tretinoin) prevents skin atrophy in mice treated with topical corticosteroids, but such studies have not been performed in humans. We performed an 8-week clinical, histological and biochemical study to test the ability of tretinoin to enhance efficacy and inhibit atrophogenicity of topical corticosteroids, when used in the treatment of psoriasis. In each of 20 psoriasis patients, one plaque, and its perilesional skin, was treated once daily with betamethasone dipropionate and tretinoin 0.1%, and one plaque, and its perilesional skin, treated with once daily betamethasone dipropionate and tretinoin vehicle. There was no difference in the speed or degree of improvement in plaques treated with either the topical corticosteroid/tretinoin combination or with corticosteroid alone. Light microscopy revealed a 19% reduction in epidermal thickness, in corticosteroid-treated perilesional skin, as compared with a slight (1%) increase in corticosteroid/tretinoin-treated perilesional areas (P = 0.067). Western blot analysis showed a 55% reduction in procollagen I aminopropeptide in perilesional skin treated corticosteroid alone, as compared with a 45% reduction in corticosteroid/tretinoin-treated perilesional skin. These data indicate that the addition of tretinoin does not impair the efficacy of a topical corticosteroid, in the treatment of psoriasis, and partially ameliorates epidermal atrophy produced by the topical corticosteroid.
authors.affiliation: Department of Dermatology, University of Michigan Medical Center, Ann Arbor, USA.
authors.forename: A J
authors.initials: AJ
authors.lastname: McMichael
authors.forename: C E
authors.initials: CE
authors.lastname: Griffiths
authors.forename: H S
authors.initials: HS
authors.lastname: Talwar
authors.forename: L J
authors.initials: LJ
authors.lastname: Finkel
authors.forename: E S
authors.initials: ES
authors.lastname: Rafal
authors.forename: T A
authors.initials: TA
authors.lastname: Hamilton
authors.forename: J J
authors.initials: JJ
authors.lastname: Voorhees
mesh_terms: D000287:Administration, Topical; D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001284:Atrophy / Q000139:chemically induced / Q000517:prevention & control; D001623:Betamethasone / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D015153:Blotting, Western; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D004817:Epidermis / Q000187:drug effects / Q000473:pathology*; D005260:Female; D005938:Glucocorticoids; D006801:Humans; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy*; D014212:Tretinoin / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000893:Anti-Inflammatory Agents; D005938:Glucocorticoids; D014212:Tretinoin; C011175:betamethasone-17,21-dipropionate; D001623:Betamethasone